Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tarsus PharmaceuticalsTARS +0.52%44 Net Cash per Share is $4.28 as of Jun. 2026, which is 6% below its 10-year median of 4.55. GuruFocus rates TARS with a GF Score™ of 44/100 and a GF Value™ of $156.33 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 793 Biotechnology companies, Tarsus Pharmaceuticals ranks worse than 78.94% on this metric.
Tarsus Pharmaceuticals (NAS:TARS) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Tarsus Pharmaceuticals Net Cash per Share Related Terms
Tarsus Pharmaceuticals Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Tarsus Pharmaceuticals's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TARS vs VERA, BEAM, KOD: Net Cash per Share Comparison
For the Biotechnology subindustry, Tarsus Pharmaceuticals's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tarsus Pharmaceuticals Price-to-Net-Cash vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tarsus Pharmaceuticals's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Tarsus Pharmaceuticals's Price-to-Net-Cash falls into.
Tarsus Pharmaceuticals Net Cash per Share Calculation
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Tarsus Pharmaceuticals's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tarsus Pharmaceuticals (TARS) has a Net Cash per Share of $4.28 as of Jun. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Tarsus Pharmaceuticals and its competitors. This is near median its historical median of 4.55. Over the past decade, Tarsus Pharmaceuticals' Net Cash per Share has ranged from 1.82 to 19.27. According to the industry distribution chart, Tarsus Pharmaceuticals ranks #626 out of 793 companies in the Biotechnology industry, placing it in the top 78.9%.
Is Tarsus Pharmaceuticals' Net Cash per Share too high?
Tarsus Pharmaceuticals' current Net Cash per Share of $4.28 is near median its 10-year median of 4.55. Over the past 10 years, this metric has ranged from a low of 1.82 to a high of 19.27. The Biotechnology industry median Net Cash per Share is 5.11. Tarsus Pharmaceuticals' value of $4.28 is 16.2% below this industry median. Based on the distribution chart, Tarsus Pharmaceuticals ranks #626 out of 793 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Tarsus Pharmaceuticals has a GF Score™ of 44/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Tarsus Pharmaceuticals' Net Cash per Share compare to VERA and BEAM?
According to the Biotechnology industry distribution chart, Tarsus Pharmaceuticals ranks #626 out of 793 companies for Net Cash per Share. This places Tarsus Pharmaceuticals in the lower half of its industry. The industry median Net Cash per Share is 5.11. Tarsus Pharmaceuticals' value of $4.28 is 16.2% below this benchmark. Historically, Tarsus Pharmaceuticals' own Net Cash per Share has ranged from 1.82 to 19.27 over the past decade. While the company's 10-year median is 4.55 vs. the industry median of 5.11, Tarsus Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Biotechnology company?
The median Net Cash per Share among Biotechnology companies is 5.11, based on 793 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tarsus Pharmaceuticals's current Net Cash per Share of $4.28 is 16.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Tarsus Pharmaceuticals and its competitors. For the Biotechnology industry, the median Net Cash per Share is 5.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tarsus Pharmaceuticals's current Net Cash per Share is $4.28, which is near median its own 10-year median of 4.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tarsus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Tarsus Pharmaceuticals (TARS) is currently considered Significantly Undervalued. The stock's GF Value™ is $156.33, compared to a current price of $69.24 — trading 55.7% below its estimated fair value. The current Net Cash per Share is $4.28, which is near median its 10-year median of 4.55 and 16.2% below the Biotechnology industry median of 5.11. Tarsus Pharmaceuticals' overall GF Score™ is 44/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Tarsus Pharmaceuticals (TARS), the current Net Cash per Share is $4.28 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tarsus Pharmaceuticals (TARS) Overvalued in 2026?
Based on GuruFocus' analysis, Tarsus Pharmaceuticals stock appears to be undervalued.
The current stock price of $69.24 is trading 55.7% below its estimated GF Value™ of $156.33.
GuruFocus considers Tarsus Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for TARS:
Net Cash per Share: $4.28 (near median its 10-year median of 4.55)
GF Value™: $156.33 vs. price of $69.24 (55.7% below fair value)
Industry Position: 16.2% below the Biotechnology median (#626 of 793)
No single metric tells the full story. See the TARS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
44GF Score
Get the complete analysis for TARS
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TARS has been successfully added to your 
